Make us your home page

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

Stimulus money to help sort out which medicines and treatments really work best

WASHINGTON — Think your doctor knows which drug — or surgery or even diagnostic test — works best? Think again.

Half the time, there's little if any good evidence comparing one with another. And one of medicine's little secrets is that new drugs don't have to work any better than cheap old ones to be approved for sale.

Now the government has a $1.1 billion down payment to start unraveling that problem, money provided in the economic stimulus package to better determine which test or treatment works best, when and for whom so patients don't waste time and money on poor choices.

But which ailments go to the top of a long wish list? And perhaps most important, how to make sure the results get into doctors' and patients' hands but not overly limit what therapies people can choose?

"There's a lot of clamor . . . that this is going to deprive people of the choice to basically have every treatment they want. That's based on a false premise," said Dr. Harold Sox, past president of the American College of Physicians. Last week, Sox was chosen to lead a panel of the prestigious Institute of Medicine to help guide what comparisons the government makes. "If people had a good explanation of why a test that they wanted was more likely to hurt them than to help them, they might of their free choice say, 'You know, I was clearly wrong. I shouldn't want that test and now I don't.' "

High-stakes comparisons

At issue is what's called "comparative effectiveness." Should you have bypass surgery or far less invasive stents to open severely clogged heart arteries? Which best prevents stroke from a clogged neck artery, surgically rooting out the clog or pushing it aside with a stent?

Does arthroscopic surgery work any better than painkillers for knee arthritis? Of all the competing pills, which is best to start with in treating Type 2 diabetes or high blood pressure? Is there really any difference between Prevacid and Prilosec for heartburn, or between Fosamax and hormone treatments for bone-weakening osteoporosis?

Those winners-and-losers questions drive fierce opposition to comparison-effectiveness research from drugmakers and others who have a financial stake in the outcome and fear that insurers will use the results to make coverage decisions. Back surgeons once lobbied to kill the federal Agency for Healthcare Research and Quality, or AHRQ, after it found "insufficient evidence" supporting certain spine operations — not that they didn't work, just that more evidence was needed.

The result: The nation has a scattershot method for determining best medicine. The little-known AHRQ spends about $30 million a year reviewing evidence of select tests and treatments. The National Institutes of Health occasionally compares contested therapies in expensive, years-long studies of thousands of patients, like the current stroke trial.

Helping the feds focus

So an extra $1.1 billion for the government to start spending on such comparisons this year marks a huge jump. By the end of June, the Institute of Medicine panel will provide a priority list of up to 50 vexing medical questions to help the feds determine where to start.

Don't expect easy answers. Federal scientists are acutely aware that many of today's studies don't account for wide variations in responses to treatments by minorities or other subgroups.

"Medical decisionmaking is rarely black-and-white," adds the NIH's heart chief Dr. Elizabeth Nabel. "We see certainly helping to provide additional evidence that really guides physicians and individuals in sorting through the shades of gray."

Stimulus money to help sort out which medicines and treatments really work best 03/11/09 [Last modified: Wednesday, March 11, 2009 5:53pm]
Photo reprints | Article reprints

Copyright: For copyright information, please check with the distributor of this item, Associated Press.

Join the discussion: Click to view comments, add yours

  1. Man convicted of second-degree murder in killing of Baby Doe, his girlfriend's daughter


    BOSTON — A man was convicted Monday of murder in the death of a 2-year-old girl who became known as Baby Doe after her remains washed up on the shore of a Boston Harbor island.

    Michael McCarthy’s friend Michael Sprinsky, far left, gets a hug from sister Laura Sprinsky after McCarthy is found guilty of second-degree murder in the death of Bella Bond, who became known as Baby Doe.
  2. Rays make Hechavarria trade official


    Here is the release from the team ...


  3. Jones: Will Tampa Bay hit a Hall of Fame dry spell now?

    Lightning Strikes

    Marty St. Louis may lack the Hall of Fame stats, but two scoring titles, an MVP award and clutch goals should count for a lot. (Dirk Shadd, Times)
  4. SeaWorld shares drop Monday to 2017 low after disclosure of federal subpoena


    The Orlando parent company of SeaWorld and Busch Gardens theme parks saw its stock drop 3.5 percent Monday to $15.10, its lowest price of this year.

    Killer whales perform at Shamu Stadium at SeaWorld in Orlando in 2011, before public pressure was placed on the theme park company to curtail its orca shows.SeaWorld has since announced an end to the traditional killer whale entertainment  at its theme parks. [AP Photo/Phelan M. Ebenhack]
  5. Update: Scientology cancels planned mock FBI raid on downtown building

    Special Topics

    CLEARWATER — The Church of Scientology planned to film a mock FBI raid on a downtown building Monday afternoon, but the actors and cameras never showed up to the location disclosed to the city.

    According to Clearwater Police, the Church of Scientology plans to hold a mock FBI raid at 3 p.m. Monday at this vacant building at 305 N Fort Harrison Ave. Police announced the raid in advance to alert the public. They said they did not know the reason for the event. [Google Earch image]